A randomized open-label study to compare the safety and efficacy of conversion from a calcineurin inhibitor to sirolimus vs continued use of a calcineurin inhibitor in heart transplant recipients with mild-moderate impaired renal function

Trial Profile

A randomized open-label study to compare the safety and efficacy of conversion from a calcineurin inhibitor to sirolimus vs continued use of a calcineurin inhibitor in heart transplant recipients with mild-moderate impaired renal function

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2016

At a glance

  • Drugs Sirolimus (Primary) ; Calcineurin inhibitors; Ciclosporin; Tacrolimus
  • Indications Heart transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 09 Jul 2012 Results published in the American Journal of Transplantation.
    • 04 May 2011 Results presented at the American Transplant Congress -- 11th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
    • 16 Apr 2011 Results presented at the 31st Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top